Olmesartan E Idroclorotiazide Zentiva (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmesartan E Idroclorotiazide Zentiva, is an angiotensin II receptor blocker presented as a oral tablet for systemic use. It treats hypertension, often in combination with a diuretic, in adult patients. GNH USA supplies Olmesartan E Idroclorotiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan E Idroclorotiazide Zentiva is marketed in the EU and conforms to European regulatory standards.

Olmesartan E Idroclorotiazide Zentiva is used primarily for cardiovascular conditions that involve elevated blood pressure.

- Hypertension: Lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure: Assists in managing fluid overload when used with other heart‑failure therapies. - Diabetic nephropathy : Helps protect the kidneys by controlling blood pressure in patients with type 2 diabetes.

Common Side Effects: - Headache   -            ... ...    …  …  ...  … … ... ... ....  …  … … …  ...  ... …  …  …  … … ......  …  …  …  … …  …  …  … … … 

Serious or       … ");

Ol  a  t 

    t \